An Insight to the Molecular Interactions of the FDA Approved HIV PR Drugs Against L38L↑N↑L PR Mutant

Overview

Journal J Comput Aided Mol Des

Publisher Springer

Specialties Biomedical Engineering
Molecular Biology

Date 2018 Feb 5

PMID 29397520

Citations 3

Authors

Zainab K Sanusi

Thavendran Govender

Glenn E M Maguire

Sibusiso B Maseko

Johnson Lin

Hendrik G Kruger

Bahareh Honarparvar

Affiliations

Soon will be listed here.

Abstract

The aspartate protease of the human immune deficiency type-1 virus (HIV-1) has become a crucial antiviral target in which many useful antiretroviral inhibitors have been developed. However, it seems the emergence of new HIV-1 PR mutations enhances drug resistance, hence, the available FDA approved drugs show less activity towards the protease. A mutation and insertion designated L38L↑N↑L PR was recently reported from subtype of C-SA HIV-1. An integrated two-layered ONIOM (QM:MM) method was employed in this study to examine the binding affinities of the nine HIV PR inhibitors against this mutant. The computed binding free energies as well as experimental data revealed a reduced inhibitory activity towards the L38L↑N↑L PR in comparison with subtype C-SA HIV-1 PR. This observation suggests that the insertion and mutations significantly affect the binding affinities or characteristics of the HIV PIs and/or parent PR. The same trend for the computational binding free energies was observed for eight of the nine inhibitors with respect to the experimental binding free energies. The outcome of this study shows that ONIOM method can be used as a reliable computational approach to rationalize lead compounds against specific targets. The nature of the intermolecular interactions in terms of the host-guest hydrogen bond interactions is discussed using the atoms in molecules (AIM) analysis. Natural bond orbital analysis was also used to determine the extent of charge transfer between the QM region of the L38L↑N↑L PR enzyme and FDA approved drugs. AIM analysis showed that the interaction between the QM region of the L38L↑N↑L PR and FDA approved drugs are electrostatic dominant, the bond stability computed from the NBO analysis supports the results from the AIM application. Future studies will focus on the improvement of the computational model by considering explicit water molecules in the active pocket. We believe that this approach has the potential to provide information that will aid in the design of much improved HIV-1 PR antiviral drugs.

Citing Articles

Design of New Schiff-Base Copper(II) Complexes: Synthesis, Crystal Structures, DFT Study, and Binding Potency toward Cytochrome P450 3A4.

Yusuf T, Oladipo S, Zamisa S, Kumalo H, Lawal I, Lawal M ACS Omega. 2021; 6(21):13704-13718.

PMID: 34095663 PMC: 8173565. DOI: 10.1021/acsomega.1c00906.

Mechanisms of Proteolytic Enzymes and Their Inhibition in QM/MM Studies.

Elsasser B, Goettig P Int J Mol Sci. 2021; 22(6).

PMID: 33810118 PMC: 8004986. DOI: 10.3390/ijms22063232.

Evaluating the Performance of a Non-Bonded Cu Model Including Jahn-Teller Effect into the Binding of Tyrosinase Inhibitors.

Martins L, Lameira J, Kruger H, Alves C, Silva J Int J Mol Sci. 2020; 21(13).

PMID: 32640730 PMC: 7369908. DOI: 10.3390/ijms21134783.

References

Brown D, Arzumanov A, Turner J, Stetsenko D, Lever A, Gait M . Antiviral activity of steric-block oligonucleotides targeting the HIV-1 trans-activation response and packaging signal stem-loop RNAs. Nucleosides Nucleotides Nucleic Acids. 2005; 24(5-7):393-6. DOI: 10.1081/ncn-200059813. View

Hodge C, Aldrich P, Bacheler L, Chang C, Eyermann C, Garber S . Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450. Chem Biol. 1996; 3(4):301-14. DOI: 10.1016/s1074-5521(96)90110-6. View

Mildner A, Rothrock D, Leone J, Bannow C, Lull J, Reardon I . The HIV-1 protease as enzyme and substrate: mutagenesis of autolysis sites and generation of a stable mutant with retained kinetic properties. Biochemistry. 1994; 33(32):9405-13. DOI: 10.1021/bi00198a005. View

Brik A, Wong C . HIV-1 protease: mechanism and drug discovery. Org Biomol Chem. 2003; 1(1):5-14. DOI: 10.1039/b208248a. View

Smith R, Brereton I, Chai R, Kent S . Ionization states of the catalytic residues in HIV-1 protease. Nat Struct Biol. 1996; 3(11):946-50. DOI: 10.1038/nsb1196-946. View

Li D, Ji B, Hwang K, Huang Y . Strength of hydrogen bond network takes crucial roles in the dissociation process of inhibitors from the HIV-1 protease binding pocket. PLoS One. 2011; 6(4):e19268. PMC: 3084818. DOI: 10.1371/journal.pone.0019268. View

Cole J, Murray C, Nissink J, Taylor R, Taylor R . Comparing protein-ligand docking programs is difficult. Proteins. 2005; 60(3):325-32. DOI: 10.1002/prot.20497. View

Honarparvar B, Makatini M, Pawar S, Petzold K, Soliman M, Arvidsson P . Pentacycloundecane-diol-based HIV-1 protease inhibitors: biological screening, 2D NMR, and molecular simulation studies. ChemMedChem. 2012; 7(6):1009-19. DOI: 10.1002/cmdc.201100512. View

Kozisek M, Bray J, rezacova P, Saskova K, Brynda J, Pokorna J . Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants. J Mol Biol. 2007; 374(4):1005-16. DOI: 10.1016/j.jmb.2007.09.083. View

10.

KATZ R, Skalka A . The retroviral enzymes. Annu Rev Biochem. 1994; 63:133-73. DOI: 10.1146/annurev.bi.63.070194.001025. View

11.

Yedidi R, Garimella H, Aoki M, Aoki-Ogata H, Desai D, Chang S . A conserved hydrogen-bonding network of P2 bis-tetrahydrofuran-containing HIV-1 protease inhibitors (PIs) with a protease active-site amino acid backbone aids in their activity against PI-resistant HIV. Antimicrob Agents Chemother. 2014; 58(7):3679-88. PMC: 4068604. DOI: 10.1128/AAC.00107-14. View

12.

Tie Y, Wang Y, Boross P, Chiu T, Ghosh A, Tozser J . Critical differences in HIV-1 and HIV-2 protease specificity for clinical inhibitors. Protein Sci. 2012; 21(3):339-50. PMC: 3375435. DOI: 10.1002/pro.2019. View

13.

Makatini M, Petzold K, Alves C, Arvidsson P, Honarparvar B, Govender P . Synthesis, 2D-NMR and molecular modelling studies of pentacycloundecane lactam-peptides and peptoids as potential HIV-1 wild type C-SA protease inhibitors. J Enzyme Inhib Med Chem. 2012; 28(1):78-88. DOI: 10.3109/14756366.2011.633907. View

14.

Dhanavade M, Jalkute C, Barage S, Sonawane K . Homology modeling, molecular docking and MD simulation studies to investigate role of cysteine protease from Xanthomonas campestris in degradation of Aβ peptide. Comput Biol Med. 2013; 43(12):2063-70. DOI: 10.1016/j.compbiomed.2013.09.021. View

15.

Maseko S, Padayachee E, Govender T, Sayed Y, Kruger G, Maguire G . I36T↑T mutation in South African subtype C (C-SA) HIV-1 protease significantly alters protease-drug interactions. Biol Chem. 2017; 398(10):1109-1117. DOI: 10.1515/hsz-2017-0107. View

16.

Palmisano L, Vella S . A brief history of antiretroviral therapy of HIV infection: success and challenges. Ann Ist Super Sanita. 2011; 47(1):44-8. DOI: 10.4415/ANN_11_01_10. View

17.

Hensen C, Hermann J, Nam K, Ma S, Gao J, Holtje H . A combined QM/MM approach to protein--ligand interactions: polarization effects of the HIV-1 protease on selected high affinity inhibitors. J Med Chem. 2004; 47(27):6673-80. DOI: 10.1021/jm0497343. View

18.

Nijhuis M, van Maarseveen N, Lastere S, Schipper P, Coakley E, Glass B . A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism. PLoS Med. 2007; 4(1):e36. PMC: 1769415. DOI: 10.1371/journal.pmed.0040036. View

19.

Fong P, McNamara J, Hillier I, Bryce R . Assessment of QM/MM scoring functions for molecular docking to HIV-1 protease. J Chem Inf Model. 2009; 49(4):913-24. DOI: 10.1021/ci800432s. View

20.

Pawar S, Jabgunde A, Maguire G, Kruger H, Sayed Y, Soliman M . Linear and cyclic glycopeptide as HIV protease inhibitors. Eur J Med Chem. 2013; 60:144-54. DOI: 10.1016/j.ejmech.2012.11.018. View